Global Adalimumab Biosimilar Market, by Product
Global Adalimumab Biosimilar Market, by Application
Global Adalimumab Biosimilar Market, by Distribution Channel
Global Adalimumab Biosimilar Market, by Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Adalimumab Biosimilar Market Snapshot
Chapter 4. Global Adalimumab Biosimilar Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Clinical Trial/Pipeline Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. By Product, & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Product:
5.2.1. Amjevita
5.2.2. Cyltezo
5.2.3. Hadlima
5.2.4. Yusimry
5.2.5. Hulio
5.2.6. Hymiroz
5.2.7. Abrilada
5.2.8. Yuflyma
5.2.9. Exemptia
5.2.10. Adalirel
5.2.11. Cipleumab
5.2.12. Other pipeline products
Chapter 5. Market Segmentation 2: By Application Estimates & Trend Analysis
5.3. By Application & Market Share, 2024 & 2034
5.4. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
5.4.1. Rheumatoid Arthritis
5.4.2. Juvenile Idiopathic Arthritis
5.4.3. Psoriatic Arthritis
5.4.4. Crohn’s Disease
5.4.5. Ankylosing Spondylitis
5.4.6. Ulcerative Colitis
5.4.7. Psoriasis
Chapter 5. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
5.5. By Distribution Channel & Market Share, 2024 & 2034
5.6. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
5.6.1. Hospital Pharmacy
5.6.2. Online Pharmacy
5.6.3. Retail Pharmacy
5.6.4. Other Direct Distribution Channels
Chapter 5. Adalimumab Biosimilar Market Segmentation 5: Regional Estimates & Trend Analysis
5.7. North America
5.7.1. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Product, 2021-2034
5.7.2. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
5.7.3. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.7.4. North America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
5.8. Europe
5.8.1. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Product, 2021-2034
5.8.2. Europe Adalimumab Biosimilar Market revenue (US$ Million) By Application, 2021-2034
5.8.3. Europe Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.8.4. Europe Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
5.9. Asia Pacific
5.9.1. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Product, 2021-2034
5.9.2. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) By Application, 2021-2034
5.9.3. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.9.4. Asia Pacific Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
5.10. Latin America
5.10.1. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Product, (US$ Million) 2021-2034
5.10.2. Latin America Adalimumab Biosimilar Market revenue (US$ Million) By Application, (US$ Million) 2021-2034
5.10.3. Latin America Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.10.4. Latin America Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
5.11. Middle East & Africa
5.11.1. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Product, (US$ Million) 2021-2034
5.11.2. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) By Application, (US$ Million) 2021-2034
5.11.3. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
5.11.4. Middle East & Africa Adalimumab Biosimilar Market revenue (US$ Million) by country, 2021-2034
Chapter 6. Competitive Landscape
6.1. Major Mergers and Acquisitions/Strategic Alliances
6.2. Company Profiles
6.2.1. Alvotech
6.2.2. Amgen Inc.
6.2.3. Biocon
6.2.4. Biosimilar Collaborations Ireland Limited
6.2.5. Boeheringer Ingelheim
6.2.6. Celltrion, Inc.
6.2.7. Coherus Biosciences
6.2.8. Cordavis Ltd.
6.2.9. Fresenius Kabi
6.2.10. Glenmark Pharmaceuticals
6.2.11. Hetero
6.2.12. Innovent Biologics
6.2.13. Kyowa Hakko Kirin (Fujifilm Kyowa Kirin Biologics)
6.2.14. Mylan
6.2.15. Mylan Pharmaceuticals Inc.
6.2.16. Organon & Co.
6.2.17. Organon/Samsung Bioepis
6.2.18. Pfizer
6.2.19. Samsung Bioepis
6.2.20. Sandoz
6.2.21. Stada Arzneimittel AG
6.2.22. Synermore
6.2.23. Teva
6.2.24. Torrent Pharmaceuticals
6.2.25. Zydus Cadila
6.2.26. Other prominent players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.